Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU

Enrolling by invitationOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Phenylketonurias
Interventions
DRUG

Pegvaliase-Pqpz

Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. \[Note that prescription and standard care are independent of the present study.\]

Trial Locations (2)

65211

University of Missouri, Columbia

02115

Boston Children's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

University of Missouri-Columbia

OTHER